Kentucky Retirement Systems Has $1.31 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Kentucky Retirement Systems lessened its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,586 shares of the medical equipment provider’s stock after selling 240 shares during the quarter. Kentucky Retirement Systems’ holdings in Hologic were worth $1,306,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in HOLX. PNC Financial Services Group Inc. lifted its stake in shares of Hologic by 0.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 31,933 shares of the medical equipment provider’s stock valued at $2,282,000 after acquiring an additional 288 shares during the period. Coldstream Capital Management Inc. acquired a new position in Hologic in the fourth quarter valued at about $305,000. D.A. Davidson & CO. acquired a new position in Hologic in the fourth quarter valued at about $204,000. Corient Private Wealth LLC lifted its stake in Hologic by 251.1% in the fourth quarter. Corient Private Wealth LLC now owns 51,106 shares of the medical equipment provider’s stock valued at $3,652,000 after buying an additional 36,550 shares during the period. Finally, SageView Advisory Group LLC acquired a new position in Hologic in the fourth quarter valued at about $289,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 1.2 %

NASDAQ:HOLX opened at $81.39 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The company has a market cap of $18.99 billion, a PE ratio of 41.53, a PEG ratio of 2.53 and a beta of 0.98. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.67. The stock has a 50-day simple moving average of $80.82 and a 200 day simple moving average of $77.12.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period last year, the company earned $0.93 earnings per share. On average, sell-side analysts expect that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on HOLX shares. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, September 17th. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Evercore ISI increased their target price on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. Stephens restated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. increased their price target on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Insider Buying and Selling at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 over the last ninety days. 1.75% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.